RECURSION PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $133.38M, a 1096.76% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $254.46M, a 1399.65% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $100.00M, a 61.77% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $41.02M, a 277.30% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2025 was $528.86M, a 75.98% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $300.53M, a 134.62% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $128.09M, a 10.87% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $143.71M, a 68.92% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $133.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $528.86M 10-K · filed 2026-02-25 |
| 2025-09-30 | $254.46M 10-Q · filed 2025-11-05 | $406.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $100.00M 10-Q · filed 2026-08-05 | $169.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $41.02M 10-Q · filed 2026-05-06 | $330.68M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $11.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $300.53M 10-K · filed 2026-02-25 |
| 2024-09-30 | $16.97M 10-Q · filed 2025-11-05 | $276.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $261.55M 10-Q · filed 2025-08-05 | $301.72M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $10.87M 10-Q · filed 2025-05-05 | $138.97M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$12.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $128.09M 10-K · filed 2026-02-25 |
| 2023-09-30 | $42.23M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $98.79M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $143.71M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $462.35M 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | |
| 2021-06-30 | $462.35M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |